

**Date: October 2, 2023**

**To: Iowa Vaccines for Children (VFC) Program Providers**

**From: Iowa VFC Program**

**Re: Vaccine Update – Nirsevimab (Beyfortus)**

Effective October 2, 2023, the Iowa VFC Program will implement and allow ordering of Nirsevimab (Beyfortus).

Nirsevimab (Beyfortus) is a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) among infants aged <8 months born during or entering their first RSV season and infants and children 8-19 months who are at increased risk for severe RSV disease and entering their second RSV season.

A detailed Beyfortus vaccine summary is available on the [VFC Program Website](#) and includes information on use, dosage, schedule, and contraindications.

### **VFC Program Ordering**

Due to the anticipated limited allocation of Beyfortus, clinics should order small quantities initially. This will allow initial uptake to be determined and will prevent possible wastage. Based on limited inventory, it may be necessary for the Program to reduce provider orders. Please order smaller quantities of Beyfortus initially until the uptake of this product is identified, which will prevent possible wastage.

**VFC providers should continue to place routine vaccine orders consistent with their economic order quantity (monthly, bimonthly or quarterly) and monitor existing inventory to ensure VFC vaccine is not wasted or allowed to expire.**

Vaccine wastage and unnecessary vaccine expiration may result in restitution per the [Vaccine Restitution Policy](#).

For questions, contact the Iowa VFC Program at [iowaVFC@hhs.iowa.gov](mailto:iowaVFC@hhs.iowa.gov).